Company: INMB
Filing Date: 2025-06-16
Form Type: S-8
Source: 0001213900-25-054428
Chunk: 5

Company: Inmune Bio, Inc.
Filing Date: 2025-06-16
Form: S-8
Chunk 5
---

operate and our beliefs and assumptions regarding these economies and markets.

Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties. We have based these forward-looking statements on assumptions and assessments made by our
management in light of their experience and their perception of historical trends, current conditions, expected future developments, and
other factors they believe to be appropriate.

Important factors that could cause actual results, developments and
business decisions to differ materially from those anticipated in these forward-looking statements include, among others, those factors
referred to in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which is incorporated by reference herein.

These statements are only current predictions and are subject to known
and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance,
or achievements to be materially different from those anticipated by the forward-looking statements. We discuss many of these risks in
the documents incorporated by reference herein. You should not rely upon forward-looking statements as predictions of future events.

Although we believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by
law, we are under no duty to update or revise any of the forward-looking statements, whether as a result of new information, future events
or otherwise, after the date of this reoffer prospectus.

<div align='center'>ii

PROSPECTUS SUMMARY</div>

This reoffer prospectus is part of the Registration Statement that we filed with the SEC. We have provided to you in this reoffer prospectus a general description of the selling stockholders and the distribution of the shares of common stock. To the extent there is a conflict between the information contained in this reoffer prospectus and any of our subsequent filings with the SEC, the information in the document having the later date shall modify or supersede the earlier statement.

As permitted by the rules and regulations of the SEC, the Registration Statement of which this reoffer prospectus forms a part includes additional information not contained in this reoffer prospectus. You may read the Registration Statement and the other reports we file with the SEC at the SEC’s website or at our website as described above under the heading “Incorporation of Certain Documents by Reference.”

In this reoffer prospectus, the “Company,” “we,” “us” and “our” refer to INmune Bio Inc